Allopurinol Use during Pregnancy - Outcome of 31 Prospectively Ascertained Cases and a Phenotype Possibly Indicative for Teratogenicity

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Hoeltzenbein, Maria ^a   Stieler, Katja ^a   Panse, Mary ^a   Wacker, Evelin ^a   Schaefer, Christof ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CYCLOSPORIN A; DIHYDRALAZINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; METHYLDOPA; MOXONIDINE; MYCOPHENOLIC ACID; PYRIDOXINE; SODIUM CARBONATE; VALSARTAN; TERATOGENIC AGENT;

ADULT; ARTICLE; CESAREAN SECTION; CHORIOAMNIONITIS; CHRONIC MYELOID LEUKEMIA; CLEFT LIP; CLEFT PALATE; CLINICAL ARTICLE; CONGENITAL MALFORMATION; CONTROLLED STUDY; CRYPTORCHISM; EAR MALFORMATION; EDEMA; FEMALE; FETUS OUTCOME; FIRST TRIMESTER PREGNANCY; GOUT; HEARING IMPAIRMENT; HUMAN; HYPEROXALURIA; HYPERTENSION; HYPERURICEMIA; HYPOPARATHYROIDISM; KIDNEY DISEASE; KIDNEY HYPOPLASIA; MICROPENIS; MICROPHTHALMIA; OXALOSIS 1; PREECLAMPSIA; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TERATOGENICITY; PREGNANCY; PREGNANCY COMPLICATIONS; THERAPEUTIC ABORTION; TUMOR LYSIS SYNDROME;

ABORTION, THERAPEUTIC; ALLOPURINOL; FEMALE; GOUT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PROSPECTIVE STUDIES; TERATOGENS; TUMOR LYSIS SYNDROME;

EID: 84879207826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066637     Document Type: Article

References (30)

1. Struthers A, Shearer F, (2012) Allopurinol: novel indications in cardiovascular disease. Heart 98: 1543-1545 heartjnl-2012-302249 [pii];10.1136/heartjnl-2012-302249 [doi].
2. Miller SL, Wallace EM, Walker DW, (2012) Antioxidant therapies: a potential role in perinatal medicine. Neuroendocrinology 96: 13-23 000336378 [pii];10.1159/000336378 [doi].
3. Hoentjen F, Seinen ML, Hanauer SB, de Boer NK, Rubin DT, et al. (2012) Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis. 10.1002/ibd.23021 [doi].
4. Seinen ML, de Boer NK, Smid K, van Asseldonk DP, Bouma G, et al. (2011) Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series. Nucleosides Nucleotides Nucleic Acids 30: 1085-1090 10.1080/15257770.2011.597371 [doi].
5. Seinen ML, de Boer NK, van Hoorn ME, van Bodegraven AA, Bouma G (2012) Safe use of allopurinol and low-dose mercaptopurine therapy during pregnancy in an ulcerative colitis patient. Inflamm Bowel Dis. 10.1002/ibd.22945 [doi].
6. Kozenko M, Grynspan D, Oluyomi-Obi T, Sitar D, Elliott AM, et al. (2011) Potential teratogenic effects of allopurinol: a case report. Am J Med Genet A 155A: 2247-2252 10.1002/ajmg.a.34139 [doi].
7. Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C, (2008) Using observational cohort data for studying drug effects on pregnancy outcome-methodological considerations. Reprod Toxicol 26: 36-41.
8. Merks JH, van Karnebeek CD, Caron HN, Hennekam RC, (2003) Phenotypic abnormalities: terminology and classification. Am J Med Genet A 123A: 211-230.
9. Rasmussen SA, Olney RS, Holmes LB, Lin AE, Keppler-Noreuil KM, et al. (2003) Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Mol Teratol 67: 193-201.
10. Voigt M, Rochow N, Hesse V, Olbertz D, Schneider KT, et al. (2010) Kurzmitteilung zu den Perzentilenwerten für die Körpermaße der Neugeborenen. Z Geburtshilfe Neonatol 214: 24-29.
11. Meister R, Schaefer C, (2008) Statistical methods for estimating the probability of spontaneous abortion in observational studies-analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 26: 31-35.
12. Coddington CC, Albrecht RC, Cefalo RC (1979) Gouty nephropathy and pregnancy. Am J Obstet Gynecol 133: 107-108. 0002-9378(79)90420-4 [pii].
13. Brown ML, Strauss B, Glasser SR, (2001) Chemotherapy in treatment of non-hodgkin's lymphoma in pregnancy (Abstract). Obstet Gynecol 97: S39.
14. Gulmezoglu AM, Hofmeyr GJ, Oosthuisen MM, (1997) Antioxidants in the treatment of severe pre-eclampsia: an explanatory randomised controlled trial. Br J Obstet Gynaecol 104: 689-696.
15. Farber M, Knuppel RA, Binkiewicz A, Kennison RD, (1976) Pregnancy and von Gierke's disease. Obstet Gynecol 47: 226-228.
16. Ali R, Ozkalemkas F, Kimya Y, Koksal N, Ozkocaman V, et al. (2009) Pregnancy in chronic lymphocytic leukemia: experience with fetal exposure to chlorambucil. Leuk Res 33: 567-569 S0145-2126(08)00273-7 [pii];10.1016/j.leukres.2008.05.019 [doi].
17. Fujii T, Nishimura H, (1972) Comparison of teratogenic action of substances related to purine metabolism in mouse embryos. Jpn J Pharmacol 22: 201-206.
18. Bragonier JR, Roesky N, Carver MJ, (1964) Teratogenesis: Effects of substituted purines and the influence of the 4 hydroxypyrazolonpyrimidine in the rat. Proc Soc Exp Biol Med 116: 685-688.
19. Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, et al. (2012) Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 158A: 588-596 10.1002/ajmg.a.35223 [doi].
20. Briggs GG, Freeman RK, and Yaffe SJ (2011) Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Lippincott Williams&Wilkins.
21. Anderka M, Mitchell AA, Louik C, Werler MM, Hernandez-Diaz S, et al. (2012) Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Mol Teratol 94: 22-30 10.1002/bdra.22865 [doi].
22. Stuebe AM, Landon MB, Lai Y, Spong CY, Carpenter MW, et al. (2012) Maternal BMI, glucose tolerance, and adverse pregnancy outcomes. Am J Obstet Gynecol 207: 62-67 S0002-9378(12)00482-6 [pii];10.1016/j.ajog.2012.04.035 [doi].
23. Bhole V, de VM, Rahman MM, Krishnan E, Choi H, (2010) Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. Arthritis Rheum 62: 1069-1076 10.1002/art.27338 [doi].
24. Tendron A, Gouyon JB, Decramer S, (2002) In utero exposure to immunosuppressive drugs: experimental and clinical studies. Pediatr Nephrol 17: 121-130.
25. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, et al. (2010) A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 5: 2060-2068.
26. Norby SM, Milliner DS (2004) Outcomes and complications of pregnancy in women with primary hyperoxaluria. Am J Kidney Dis 43: 277-285. S0272638603014896 [pii].
27. Waller DK, Shaw GM, Rasmussen SA, Hobbs CA, Canfield MA, et al. (2007) Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med 161: 745-750 161/8/745 [pii];10.1001/archpedi.161.8.745 [doi].
28. Carmichael SL, Rasmussen SA, Shaw GM, (2010) Prepregnancy obesity: a complex risk factor for selected birth defects. Birth Defects Res A Clin Mol Teratol 88: 804-810 10.1002/bdra.20679 [doi].
29. Carey JC, Martinez L, Balken E, Leen-Mitchell M, Robertson J, (2009) Determination of human teratogenicity by the astute clinician method: review of illustrative agents and a proposal of guidelines. Birth Defects Res A Clin Mol Teratol 85: 63-68 10.1002/bdra.20533 [doi].
30. Jones KL, Carey JC, (2011) The importance of dysmorphology in the identification of new human teratogens. Am J Med Genet C Semin Med Genet 157: 188-194 10.1002/ajmg.c.30311 [doi].